Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELTX 
Elicio Therapeutics Inc. (ELTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ELTX (3-star) is a REGULAR-BUY. BUY since 11 days. Profits (7.01%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.98% | Avg. Invested days 45 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.04M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 2 | Beta 2.15 | 52 Weeks Range 3.70 - 12.42 | Updated Date 08/30/2025 |
52 Weeks Range 3.70 - 12.42 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.98 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.67 | Actual -0.66 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -123.26% | Return on Equity (TTM) -60013.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 164856130 | Price to Sales(TTM) - |
Enterprise Value 164856130 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 16338300 | Shares Floating 10640361 |
Shares Outstanding 16338300 | Shares Floating 10640361 | ||
Percent Insiders 42.96 | Percent Institutions 9.49 |
Upturn AI SWOT
Elicio Therapeutics Inc.
Company Overview
History and Background
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies based on its Amphiphile technology. Founded in 2011, it aims to enhance and target the immune response for cancer treatment.
Core Business Areas
- Immunotherapies: Development of novel immunotherapies for treating cancer using the Amphiphile platform to directly target and activate immune cells.
Leadership and Structure
The company is led by a management team with experience in drug development and oncology. Details about the organizational structure are less publicly available but typically follow a biotech company setup with departments for R&D, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- ELI-002 2P: A structured Amphiphile (AMP) mKRAS-directed therapeutic cancer vaccine designed to target KRAS-driven cancers. It is currently in clinical development. There is no available data for market share or specific revenue at this time. Competitors include companies developing other KRAS-targeted therapies and cancer vaccines.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, with advancements in personalized medicine and targeted therapies. There's a high demand for innovative approaches to treat cancer.
Positioning
Elicio Therapeutics positions itself by focusing on improving cancer immunotherapy by leveraging its Amphiphile technology to enhance immune cell targeting and activation. Its competitive advantage lies in the Amphiphile technology.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is estimated to be hundreds of billions of dollars. Elicio is positioned to capture a portion of this market with its novel targeting approach if clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Proprietary Amphiphile technology platform
- Targeted delivery of immunotherapies
- Potential for improved immune response
- Clinical-stage development
Weaknesses
- Reliance on a single technology platform
- High risk associated with drug development
- Limited financial resources compared to larger pharmaceutical companies
- No current products on the market
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Growing demand for cancer immunotherapies
Threats
- Competition from established immunotherapy companies
- Regulatory hurdles
- Clinical trial failures
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- GILD
Competitive Landscape
Elicio Therapeutics faces competition from large pharmaceutical companies. Its advantage lies in its novel Amphiphile platform, but disadvantages include limited resources.
Growth Trajectory and Initiatives
Historical Growth: Growth depends on the development of its Amphiphile technology and clinical progress.
Future Projections: Future projections rely on successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing ELI-002 2P through clinical trials and pursuing partnerships.
Summary
Elicio Therapeutics is a clinical-stage company with promising Amphiphile technology. The main challenge is that it requires considerable time and resources to test and eventually get its new line of therapeutics approved. The company will likely need partnerships and additional funding for continued research and development. It needs to watch out for other companies making advancements in immune activation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The biotech industry is dynamic and rapidly evolving; therefore, the analysis could change over time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://elicio.com |
Full time employees 32 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.